Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic
Ziqi Wang,
Kai Cui,
Ulrich Costabel,
Xiaoju Zhang
Affiliations
Ziqi Wang
Department of Respiratory and Critical Care Medicine Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou Henan P. R. China
Kai Cui
Department of Respiratory and Critical Care Medicine Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou Henan P. R. China
Ulrich Costabel
Department of Respiratory and Critical Care Medicine Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou Henan P. R. China
Xiaoju Zhang
Department of Respiratory and Critical Care Medicine Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou Henan P. R. China
Abstract Coronavirus disease 2019 (COVID‐19) continually poses a significant threat to the human race, and prophylactic vaccination is the most potent approach to end this pandemic. Nanotechnology is widely adopted during COVID‐19 vaccine development, and the engineering of nanostructured materials such as nanoparticles has opened new possibilities in innovative vaccine development by improving the design and accelerating the development process. This review aims to comprehensively understand the current situation and prospects of nanotechnology‐enabled vaccine development against the COVID‐19 pandemic, with an emphasis on the interplay between nanotechnology and the host immune system.
